TL;DR: A 2026 randomized clinical trial in JAMA Network Open found that one supervised 30 mg/70 kg psilocybin dose plus cognitive behavioral therapy produced 40.5% six-month smoking abstinence versus 10.0% with a nicotine patch plus the same therapy. Key Findings 40.5% vs. 10% prolonged abstinence at 6 months: 17 of 42 psilocybin participants stayed biochemically …
TL;DR: A 2026 study in Psychopharmacology found that after 14 days of unpredictable chronic stress, a single 1-hour ayahuasca exposure restored sociability, reduced anxiety-like behavior, normalized cortisol, and rescued whole-brain BDNF in adult zebrafish within 24 hours. Key Findings 396 fish across 6 groups: Adult zebrafish were split into stressed and non-stressed groups, then exposed …
TL;DR: A 2026 exploratory study in Nature Communications found that a first 25 mg psilocybin dose in 28 psychedelic-naive adults increased electroencephalography (EEG), a scalp recording of brain electrical activity, entropy during the acute session and that entropy predicted one-month well-being change. Key Findings 28 psychedelic-naive adults: Participants received 1 mg psilocybin as a low-dose …
TL;DR: A 2026 randomized trial in The British Journal of Psychiatry found 6 ketamine infusions improved severe treatment-resistant depression, but curated music added no measurable benefit; higher mystical-experience scores still predicted the next session’s depression outcome. Key Findings MADRS fell 11.8 points by week 4: Scores dropped from 31.5 to 19.7 (d = 1.2, p …
Fluorinated Psilocin: The Sub-Hallucinogenic Breakthrough TL;DR: Chemists designed a new psilocin derivative with fluorine modifications that induces sub-hallucinogenic effects in mice, sidestepping the acute psychological effects of classic psychedelics while retaining therapeutic serotonin receptor activity. Psilocybin has emerged as a clinical darling—mounting evidence shows rapid relief for depression, anxiety, and cluster headaches. But there’s a …
How Psychedelics Hijack Brain Waves to Create Hallucinations TL;DR: A psychedelic drug that activates serotonin receptors dramatically amplifies slow 5-Hz brain oscillations in visual and memory regions, suggesting a mechanism for how hallucinogens distort perception by letting internal signals override external reality. Visual perception feels stable, seamless, continuous. But that stability is an illusion orchestrated …
Ketamine significantly reduces suicidal ideation in depressed patients, with rapid effects observed within the first day of treatment. Highlights: Rapid Reduction: Ketamine shows a significant reduction in suicidal ideation within the first day of treatment (RR = 10.02, 95% CI = 4.24 to 23.68). Sustained Improvement: Repeated ketamine treatments result in a greater reduction of …
A study examined the effects of ketamine on sleep arousal metrics in individuals with treatment-resistant depression (TRD) vs. healthy volunteers, finding that ketamine increases certain sleep-related brain activities but does not significantly mediate its antidepressant effects through these sleep changes. Highlights: Individuals with TRD had lower total sleep time and shorter REM latency compared to …
TLDR: LSD does not provide psychological resilience during stressful experiences such as job loss – and may increase psychological distress. Highlights: The study analyzed data from 5,067,553 unemployed individuals seeking jobs. LSD users who had used the drug more than a year before job loss were the focus to ensure accurate results. LSD use prior …
Researchers uncover a surprising molecular mechanism that explains ketamine’s exceptionally long-lasting antidepressant effects. Key Facts: Ketamine’s antidepressant effects last for days after its concentration drops to low, ineffective levels only an hour after administration. This contrasts starkly with ketamine’s short 13-minute half-life in the body. Ketamine continues blocking NMDA receptors and suppressing activity in the …
